Actinium Pharmaceuticals Announces Oral Presentation at EANM 2026 Highlighting First-in-Human Phase 1 Study of ATNM-400, a Non-PSMA Targeting Radiotherapy, in Prostate Cancer

Actinium touts early Phase 1 progress for ATNM-400 but provides no clinical data.

What the company is saying

Actinium Pharmaceuticals is highlighting the upcoming oral presentation of early Phase 1 clinical data for ATNM-400, a first-in-class Actinium-225 antibody radioconjugate targeting a non-PSMA antigen in metastatic castration-resistant prostate cancer (mCRPC). The company frames ATNM-400 as a potential therapy for patients not served by PSMA-directed treatments, emphasizing its novelty and broad applicability. The announcement details the study’s focus on safety, biodistribution, and dosimetry using Zirconium-89-labeled ATNM-400, with PET imaging to inform therapeutic dosing. Sandesh Seth, Chairman and CEO, positions these initial findings as a milestone for both Actinium and the broader prostate cancer field, underscoring the drug’s potential to address treatment-resistant disease. The release also references Actinium’s broader pipeline, including Actimab-A and its collaboration with the National Cancer Institute, and notes an IP portfolio of approximately 250 patents and patent applications. The tone is optimistic and forward-looking, but the company does not disclose any actual clinical results or quantitative outcomes from the Phase 1 trial.

What the data suggests

The only realised facts are that Actinium will present early Phase 1 data for ATNM-400 at the 39th Annual Congress of the European Association of Nuclear Medicine in Vienna, Austria, on October 19, 2026, and that the study is ongoing. ATNM-400 is described as targeting a novel, non-PSMA antigen and has shown preclinical activity in mCRPC, non-small cell lung cancer, and breast cancer, but no preclinical or clinical data are provided. The company holds approximately 250 patents and patent applications, including IP related to cyclotron-based production of Ac-225. No safety, efficacy, or dosimetry results from the current trial are disclosed, nor are there any financial, revenue, or operational metrics. The announcement is descriptive of study design and pipeline breadth but lacks evidence of clinical progress or impact.

Analysis

The announcement is upbeat, emphasizing the potential of ATNM-400 and the company's broad pipeline, but provides no clinical efficacy, safety, or quantitative outcome data from the ongoing Phase 1 trial. Most key claims are forward-looking, such as the potential to serve a broad mCRPC population and advancement toward later-stage trials, without supporting evidence from realised results. The only realised facts are the presentation of early Phase 1 data at a scientific congress, the existence of the ongoing trial, and the company's patent portfolio. There is no disclosure of financial metrics, clinical results, or operational milestones achieved, limiting the ability to assess tangible progress. The language inflates the significance of early-stage developments and preclinical activity, projecting broad future impact without substantiating data. While the pipeline breadth and IP position are factual, the gap between narrative and evidence is material.

Risk flags

• ●The absence of disclosed clinical data from the Phase 1 trial means there is no evidence yet of safety, efficacy, or pharmacokinetics for ATNM-400, making the program’s future highly uncertain.
• ●Claims about ATNM-400’s potential to address PSMA-low and PSMA-negative mCRPC, and to serve patients refractory to PSMA-directed therapies, are unsupported by trial data, increasing the risk that the drug may not deliver on these promises.
• ●The company’s pipeline is broad and IP portfolio is large, but without financial or operational disclosures, it is unclear whether Actinium has the resources to advance multiple programs through costly late-stage development.
• ●Execution risk is high for first-in-class radiotherapeutics, especially given the complexity of targeted alpha therapies and the need for specialized production and regulatory pathways.

Bottom line

This announcement signals that Actinium is progressing its ATNM-400 program into early human studies and will share initial findings at a major European nuclear medicine conference. While the company emphasizes the novelty and broad potential of ATNM-400, investors are given no clinical data, safety results, or quantitative outcomes to evaluate the program’s prospects. The narrative is aspirational, relying on preclinical activity and study design rather than realised milestones. The breadth of the pipeline and patent portfolio is noted, but the lack of financial or operational detail leaves open questions about execution capacity. Investors should treat this as an early-stage update with no actionable efficacy or safety signal. The most important takeaway is that the program remains in the earliest clinical stage, and future value depends entirely on forthcoming trial results.

Announcement summary

(NYSE American: ATNM) Actinium Pharmaceuticals, Inc. announced that early clinical data from the first-in-human Phase 1 study of ATNM-400 in metastatic castration-resistant prostate cancer (mCRPC) will be presented at the 39th Annual Congress of the European Association of Nuclear Medicine (EANM), held October 17–21, 2026, in Vienna, Austria. The oral presentation will focus on the ongoing Phase 1 dose-escalation study of ATNM-400 in mCRPC. ATNM-400 is described as a first-in-class Actinium-225 (²²⁵Ac) antibody radioconjugate targeting a non-PSMA antigen implicated in tumor survival and treatment resistance. The study is designed to characterize the safety, biodistribution, and dosimetry of Zirconium-89-labeled ATNM-400. Serial PET imaging is being used to assess tumor uptake, distribution, and clearance, with dosimetry estimates informing therapeutic ²²⁵Ac-ATNM-400 dosing. Sandesh Seth, Chairman and CEO of Actinium, stated that these initial clinical data represent an important milestone for both Actinium and prostate cancer treatment beyond PSMA. He emphasized that ATNM-400 has the potential to serve a broad mCRPC population, including patients with PSMA-low or PSMA-negative disease and those who do not respond to or progress after PSMA-directed therapies. The EANM 2026 presentation details include Abstract Number OP-525, oral presentation type, Session 1111 (Theranostics Track: Prostate Cancer Therapy II), scheduled for Monday, October 19, 2026, from 4:45–6:15 p.m. CEST in Hall G1, Vienna, Austria. Actinium's pipeline includes solid tumor therapeutics such as ATNM-400 and Actimab-A, with Actimab-A advancing toward a Phase 2/3 trial in relapsed/refractory AML and additional development through a CRADA with the National Cancer Institute (NCI). ATNM-400 targets a novel antigen distinct from PSMA and has demonstrated preclinical activity in mCRPC, non-small cell lung cancer (NSCLC), and breast cancer. Actinium is also advancing preclinical solid tumor programs and holds approximately 250 patents and patent applications, including intellectual property related to cyclotron-based production of Ac-225. The company employs a biology-driven approach to develop differentiated radiopharmaceuticals for solid tumors and hematologic malignancies.

Disagree with this article?